In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Targeted Therapeutics: Linking EGF Receptor Drugs to Diagnostics

Executive Summary

Herceptin-HerceptTest is a successful model of the benefits of linking a therapeutic to a diagnostic test, but the ties aren't as clear-cut in the next crop of targeted therapies to come to market. EGF receptor-based drugs work on specific receptor targets in a variety of cancers, but scientists haven't been able so far to correlate patient response to the drugs to receptor presence or quantity. Yet the issue is extremely important, both to pharma companies seeking to determine how they will design their clinical trials and submit data to the FDA and to diagnostic companies looking for a new kind of market.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts